A Randomised, Double-blind, Placebo Controlled, Double Dummy, Single-centre Trial in Healthy Subjects Comparing the Steady-state Exposure of Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 19 Apr 2016 Status changed from active, no longer recruiting to completed.
- 12 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 25 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.